Aomics GmbH

Aomics GmbH

Biotechnologieforschung

Eschborn, Hesse 1.688 Follower:innen

Analytics-driven risk reduction in immunotherapy development

Info

Aomics boosts immuno-oncology research with cost-efficient biometric solutions for SMEs. In the rapidly evolving field of immunotherapy, reducing risks is paramount to successful and safe treatment development. At the heart of our approach lies analytics-driven risk reduction, powered by advanced multi-omics data analytics and specialized immuno-informatics. By integrating and analyzing diverse data sets, including genomics, transcriptomics, proteomics, and metabolomics, we uncover comprehensive insights into the immune response mechanisms. Our immuno-informatics focus allows us to predict potential immune related adverse effects (irAEs), identify biomarkers, and optimize therapeutic strategies, ensuring that every step in the immunotherapy development process is backed by precise, data-driven decisions. This holistic approach not only accelerates the path to innovative treatments but also enhances their safety and efficacy, ultimately transforming patient outcomes. For further clinical developments of the new therapies, we provide comprehensive statistical consulting, programming, and CDM services, with a particular focus on Oncology studies.

Branche
Biotechnologieforschung
Größe
2–10 Beschäftigte
Hauptsitz
Eschborn, Hesse
Art
Privatunternehmen
Gegründet
2019
Spezialgebiete
Machine learning, Healthcare data analysis, AI, Biological model development, Bioinformatics, Biological data analysis, precision medicine, Personalized medicine, Immunoinformatics, Immuno-oncology., Clinical Development, Biostatistics , Statistical Programming, clinical research, CRO, Contract Research Organisation, Clinical Trials, Clinical Data Analytics, Pharmacovigilance, biostatistics programming, medical writing, study design und Regulatory compliance

Orte

Beschäftigte von Aomics GmbH

Updates

Ähnliche Seiten

Jobs durchsuchen

Finanzierung